Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters

作者：Endo Tsukude Chihiro; Sasaki Ji ichiro; Saeki Sho; Iwamoto Norihiro; Inaba Megumi; Ushijima Sunao; Kishi Hiroto; Fujii Shinji; Semba Hiroshi; Kashiwabara Kosuke; Tsubata Yukari; Hayashi Mitsuhiro; Kai Yuki; Saito Hideyuki; Isobe Takeshi; Kohrogi Hirotsugu; Hamada Akinobu

来源：Biological & Pharmaceutical Bulletin, 2018, 41(1): 47-56.

DOI：10.1248/bpb.b17-00521

• erlotinib
• population pharmacokinetics
• genetic polymorphism
• adverse event

Determinants of interindividual variability in erlotinib pharmacokinetics (PK) and adverse events remain to be elucidated. This study with 50 Japanese non-small-cell lung cancer patients treated with oral erlotinib at a standard dose of 150 mg aimed to investigate whether genetic polymorphisms affect erlotinib PK and adverse events. Single nucleotide polymorphisms (SNPs) in genes encoding metabolizing enzymes (CYP1A1, CYP1A2, CYP2D6, CYP3A4, CYP3A5, UGT1A1, UGT2B7, GSTM1, and GSTT1) or efflux transporters (ABCB1, and ABCG2) were analyzed as covariates in a population PK model. The ABCB1 1236C>T (rs1128503) polymorphism, not ABCB1*2 haplotype (1236TT-2677TT-3455TT, rs1128503 TT-rs2032582 TT-rs1045642 TT), was a significant covariate for the apparent clearance (CL/F), with the TT genotype showing a 29.4% decrease in CL/F as compared with the CC and the CT genotypes. A marginally higher incidence of adverse events (mainly skin rash) was observed in the TT genotype group; however, patients with high plasma erlotinib exposure did not always experience skin rash. None of the other SNPs affected PK or adverse events. The ABCB1 genotype is a potential predictor for erlotinib adverse events. Erlotinib might be used with careful monitoring of adverse events in patients with ABCB1 polymorphic variants.

• 出版日期2018-1